ActiGraft, a FDA-cleared regenerative wound care solution, enables health care providers to produce in vitro blood clots from a patient's whole blood. Once applied, the blood clot tissue serves as a protective covering, biologic scaffold and wound microenvironment to promote the natural wound healing processes of the body.
• Covers the wound for long periods of time with minimal care between applications
• Provides the wound with an optimal, natural healing environment allowing the healing process to proceed unhindered
• Can be easily prepared at the patient’s bed-side in 10 minutes and requires no capital equipment
• Created from the patient's blood, assuring safe and effective management of the wound
• Minimal handling of the wound provides a more comfortable treatment for patients
ActiGraft is intended to be used at point-of-care for the safe and rapid preparation of Whole Blood Clot (WBC) gel from a small sample of a patient's own peripheral blood. Under the supervision of a health care professional, the WBC gel produced by ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers and mechanically or surgically-debrided wounds
The ActiGraft System is contraindicated in patients with wounds due to malignancy or wounds with active clinically diagnosed infection.
Federal Law (U.S.A.) restricts this device to sale by or on the order of a physician. Throughout the processing and application of ActiGraft, use universal precautions as defined by the facility policy and procedure manual. All parts of the procedure shall be performed in such a manner as to minimize splashing, spattering and generation of potential droplets.
ActiGraft was not verified to be in compliance with other wound care products. Assure the patient monthly blood draw is below 250ml per month. The ActiGraft Kit includes blood-contacting components that have been sterilized by ethylene oxide, which may cause serious allergic reactions in patients that are sensitized. Failure to follow instructions may lead to suboptimal outcomes or product failure. Outcomes may vary.
Store in the original container at a controlled room temperature of 5°C (41°F) – 30°C (86°F). Protect from freezing and avoid excessive heat.
|Contact manufacturer for details|
|FDA cleared/approved for bone/tendon|
|FDA cleared/approved for burns|
|Kit components included||●|
|No centrifuge required||●|
|Portable preparation device||●|
|Same day procurement application||●|
|Educational Material Available||●|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
ActiGraft is applied weekly.
RedDress is committed to improving the health and lives of patients around the world by revolutionizing the way chronic wounds are treated. Their innovative products are advanced, biologic wound care solutions that reproduce the natural wound healing processes of the body.